| 1.44 -0.08 (-5.26%) | 12-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.77 | 1-year : | 2.07 |
| Resists | First : | 1.51 | Second : | 1.77 |
| Pivot price | 1.33  |
|||
| Supports | First : | 1.22 | Second : | 1.03 |
| MAs | MA(5) : | 1.42 |
MA(20) : | 1.29 |
| MA(100) : | 1.22 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 77.8 |
D(3) : | 74.2 |
| RSI | RSI(14): 59 |
|||
| 52-week | High : | 3.77 | Low : | 0.86 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ALLO ] has closed below upper band by 21.3%. Bollinger Bands are 26% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.51 - 1.52 | 1.52 - 1.53 |
| Low: | 1.39 - 1.4 | 1.4 - 1.41 |
| Close: | 1.42 - 1.44 | 1.44 - 1.45 |
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Sat, 29 Nov 2025
Allogene Therapeutics (NASDAQ:ALLO) Upgraded at Wall Street Zen - MarketBeat
Mon, 10 Nov 2025
Allogene (NASDAQ: ALLO) to join 3 conferences: TD Cowen, Jefferies London, Piper Sandler - Stock Titan
Mon, 10 Nov 2025
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - Allogene
Thu, 06 Nov 2025
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update - GlobeNewswire
Thu, 06 Nov 2025
Earnings call transcript: Allogene Therapeutics Q3 2025 beats EPS expectations - Investing.com
Thu, 06 Nov 2025
Allogene Therapeutics Inc (ALLO) Q3 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 225 (M) |
| Shares Float | 155 (M) |
| Held by Insiders | 16.7 (%) |
| Held by Institutions | 62.9 (%) |
| Shares Short | 18,700 (K) |
| Shares Short P.Month | 19,490 (K) |
| EPS | -0.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27.4 % |
| Return on Equity (ttm) | -54.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.75 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.95 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -158 (M) |
| Levered Free Cash Flow | -84 (M) |
| PE Ratio | -1.47 |
| PEG Ratio | 0 |
| Price to Book value | 1.02 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|